Literature DB >> 9100224

Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes.

C M Eng1, G A Ashley, T S Burgert, A L Enriquez, M D'Souza, R J Desnick.   

Abstract

BACKGROUND: Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the alpha-galactosidase A (alpha-Gal A) gene located at Xq22.1. To determine the nature and frequency of the molecular lesions causing the classical and milder variant Fabry phenotypes and for precise carrier detection, the alpha-Gal A lesions in 42 unrelated Fabry hemizygotes were determined.
MATERIALS AND METHODS: Genomic DNA was isolated from affected probands and their family members. The seven alpha-galactosidase A exons and flanking intronic sequences were PCR amplified and the nucleotide sequence was determined by solid-phase direct sequencing.
RESULTS: Two patients with the mild cardiac phenotype had missense mutations, I9IT and F113L, respectively. In 38 classically affected patients, 33 new mutations were identified including 20 missense (MIT, A31V, H46R, Y86C, L89P, D92Y, C94Y, A97V, R100T, Y134S, G138R, A143T, S148R, G163V, D170V, C202Y, Y216D, N263S, W287C, and N298S), two nonsense (Q386X, W399X), one splice site mutation (IVS4 + 2T-->C), and eight small exonic insertions or deletions (304del1, 613del9, 777del1, 1057del2, 1074del2, 1077del1, 1212del3, and 1094ins1), which identified exon 7 as a region prone to gene rearrangements. In addition, two unique complex rearrangements consisting of contiguous small insertions and deletions were found in exons 1 and 2 causing L45R/H46S and L120X, respectively.
CONCLUSIONS: These studies further define the heterogeneity of mutations causing Fabry disease, permit precise carrier identification and prenatal diagnosis in these families, and facilitate the identification of candidates for enzyme replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9100224      PMCID: PMC2230047     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  22 in total

1.  Identification of mutations in the COL4A5 collagen gene in Alport syndrome.

Authors:  D F Barker; S L Hostikka; J Zhou; L T Chow; A R Oliphant; S C Gerken; M C Gregory; M H Skolnick; C L Atkin; K Tryggvason
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

2.  Fabry disease: fourteen alpha-galactosidase A mutations in unrelated families from the United Kingdom and other European countries.

Authors:  J P Davies; C M Eng; J A Hill; S Malcolm; K MacDermot; B Winchester; R J Desnick
Journal:  Eur J Hum Genet       Date:  1996       Impact factor: 4.246

3.  Nucleotide sequence of the human alpha-galactosidase A gene.

Authors:  R Kornreich; R J Desnick; D F Bishop
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

4.  The CpG dinucleotide and human genetic disease.

Authors:  D N Cooper; H Youssoufian
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

5.  Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG).

Authors:  C P Nogueira; M C McGuire; C Graeser; C F Bartels; M Arpagaus; A F Van der Spek; H Lightstone; O Lockridge; B N La Du
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

6.  Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes.

Authors:  R J Desnick; K Y Allen; S J Desnick; M K Raman; R W Bernlohr; W Krivit
Journal:  J Lab Clin Med       Date:  1973-02

7.  Identification of a distinct type IV collagen alpha chain with restricted kidney distribution and assignment of its gene to the locus of X chromosome-linked Alport syndrome.

Authors:  S L Hostikka; R L Eddy; M G Byers; M Höyhtyä; T B Shows; K Tryggvason
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

8.  Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene.

Authors:  H S Bernstein; D F Bishop; K H Astrin; R Kornreich; C M Eng; H Sakuraba; R J Desnick
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

9.  Identification of mutations leading to the Lesch-Nyhan syndrome by automated direct DNA sequencing of in vitro amplified cDNA.

Authors:  R A Gibbs; P N Nguyen; L J McBride; S M Koepf; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

10.  Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region.

Authors:  D F Bishop; R Kornreich; R J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more
  40 in total

1.  Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors.

Authors:  Robin L Bennett; Kimberly A Hart; Erin O'Rourke; John A Barranger; Jack Johnson; Kay D MacDermot; Gregory M Pastores; Robert D Steiner; Ravi Thadhani
Journal:  J Genet Couns       Date:  2002-04       Impact factor: 2.537

2.  Target-enrichment sequencing and copy number evaluation in inherited polyneuropathy.

Authors:  Wei Wang; Chen Wang; D Brian Dawson; Erik C Thorland; Patrick A Lundquist; Bruce W Eckloff; Yanhong Wu; Saurabh Baheti; Jared M Evans; Steven S Scherer; Peter J Dyck; Christopher J Klein
Journal:  Neurology       Date:  2016-04-13       Impact factor: 9.910

3.  Newborn screening for lysosomal storage disorders in hungary.

Authors:  Judit Wittmann; Eszter Karg; Sàndor Turi; Elisa Legnini; Gyula Wittmann; Anne-Katrin Giese; Jan Lukas; Uta Gölnitz; Michael Klingenhäger; Olaf Bodamer; Adolf Mühl; Arndt Rolfs
Journal:  JIMD Rep       Date:  2012-03-21

4.  Questioning the Pathogenic Role of the GLA p.Ala143Thr "Mutation" in Fabry Disease: Implications for Screening Studies and ERT.

Authors:  W Terryn; R Vanholder; D Hemelsoet; B P Leroy; W Van Biesen; G De Schoenmakere; B Wuyts; K Claes; J De Backer; G De Paepe; A Fogo; M Praet; B Poppe
Journal:  JIMD Rep       Date:  2012-07-29

5.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype.

Authors:  Satoshi Ishii; Shoichiro Nakao; Reiko Minamikawa-Tachino; Robert J Desnick; Jian-Qiang Fan
Journal:  Am J Hum Genet       Date:  2002-02-04       Impact factor: 11.025

6.  Prevalence of Fabry disease and GLA c.196G>C variant in Japanese stroke patients.

Authors:  Kiyoshiro Nagamatsu; Yoshiki Sekijima; Katsuya Nakamura; Kimitoshi Nakamura; Kiyoko Hattori; Masao Ota; Yusaku Shimizu; Fumio Endo; Shu-Ichi Ikeda
Journal:  J Hum Genet       Date:  2017-03-09       Impact factor: 3.172

7.  High incidence of later-onset fabry disease revealed by newborn screening.

Authors:  Marco Spada; Severo Pagliardini; Makiko Yasuda; Turgut Tukel; Geetha Thiagarajan; Hitoshi Sakuraba; Alberto Ponzone; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2006-04-28       Impact factor: 11.025

8.  Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease.

Authors:  A K Topaloglu; G A Ashley; B Tong; J Shabbeer; K H Astrin; C M Eng; R J Desnick
Journal:  Mol Med       Date:  1999-12       Impact factor: 6.354

9.  Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke.

Authors:  Marcella A Wozniak; Steven J Kittner; Stanley Tuhrim; John W Cole; Barney Stern; Mark Dobbins; Marie E Grace; Irina Nazarenko; Robert Dobrovolny; Eric McDade; Robert J Desnick
Journal:  Stroke       Date:  2009-12-10       Impact factor: 7.914

10.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.